Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Virology. 2018 Jan 15;514:106-117. doi: 10.1016/j.virol.2017.10.013. Epub 2017 Nov 22.
HIV-1 envelope (Env)-based vaccines have so far largely failed to induce antibodies that prevent HIV-1 infection. One factor proposed to limit the immunogenicity of cell-associated Env is its low level of expression on the cell surface, restricting accessibility to antibodies. Using a vaccinia prime/protein boost protocol in mice, we explored the immunologic effects of mutations in the Env cytoplasmic tail (CT) that increased surface expression, including partial truncation and ablation of a tyrosine-dependent endocytosis motif. After vaccinia primes, CT-modified Envs induced up to 7-fold higher gp120-specific IgG, and after gp120 protein boosts, they elicited up to 16-fold greater Tier-1 HIV-1 neutralizing antibody titers, although results were variable between isolates. These data indicate that the immunogenicity of HIV-1 Env in a prime/boost vaccine can be enhanced in a strain-dependent manner by CT mutations that increase Env surface expression, thus highlighting the importance of the prime in this vaccine format.
HIV-1 包膜 (Env)- 为基础的疫苗迄今为止在很大程度上未能诱导预防 HIV-1 感染的抗体。据推测,限制细胞相关 Env 免疫原性的一个因素是其在细胞表面的低表达水平,限制了抗体的可及性。我们使用牛痘疫苗进行初步接种/蛋白加强免疫方案,在小鼠中探索了改变 Env 细胞质尾巴 (CT) 以增加表面表达的免疫效果,包括部分截短和破坏依赖于酪氨酸的内吞作用基序。在牛痘疫苗接种后,CT 修饰的 Env 诱导高达 7 倍的 gp120 特异性 IgG,在 gp120 蛋白加强免疫后,它们引发高达 16 倍的 Tier-1 HIV-1 中和抗体滴度,尽管在不同分离株之间结果存在差异。这些数据表明,通过增加 Env 表面表达的 CT 突变,可以以菌株依赖性的方式增强 HIV-1 Env 在疫苗中的免疫原性,从而突出了该疫苗形式中初级接种的重要性。